Novo Nordisk’s (NYSE: NVO) stock surged over 12% in pre-market trading Friday after the company announced favorable early-stage clinical trial results for its latest weight loss drug, amycretin. The once-weekly injection, similar to Novo’s blockbuster drugs Wegovy and Ozempic, demonstrated up to 22% weight loss over 36 weeks in a trial involving 125 participants. The […]